Back to top
more

Aeglea BioTherapeutics, Inc. (AGLE)

(Delayed Data from NSDQ)

$6.96 USD

6.96
75,392

+0.24 (3.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.94 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

by Zacks Equity Research

Amgen's (AMGN) Repatha significantly reduces LDL-C and non-HDL-C in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia.

    Novo Nordisk (NVO) Announces Results in Diabetes Studies

    by Zacks Equity Research

    Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.

      Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA

      by Zacks Equity Research

      Bristol-Myers Squibb Company (BMY) announces that the FDA accepts its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo.

        Ironwood Initiates Phase III Studies on Reflux Candidate

        by Zacks Equity Research

        Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.

          Anika Reports Top Line Data from CINGAL Study, Shares Slump

          by Zacks Equity Research

          Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.

            Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

            by Zacks Equity Research

            Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

              Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

              by Zacks Equity Research

              Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

                Alexion (ALXN) Submits Application for ALXN1210 with FDA

                by Zacks Equity Research

                Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

                  Roche to Buy Rest of Foundation Medicine for $2.4 billion

                  by Zacks Equity Research

                  Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.

                    Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

                    by Zacks Equity Research

                    Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

                      PTC Therapeutics' Spinal Muscular Atrophy Study Successful

                      by Zacks Equity Research

                      PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

                        ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer

                        by Zacks Equity Research

                        With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.

                          Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone

                          by Zacks Equity Research

                          Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.

                            Flex Pharma Down on Workforce Reduction, Ends Phase II Study

                            by Zacks Equity Research

                            Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.

                              Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA

                              by Zacks Equity Research

                              Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.

                                Sarepta Inks Manufacturing Deal for Gene Therapy Program

                                by Zacks Equity Research

                                Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

                                  Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer

                                  by Zacks Equity Research

                                  Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.

                                    Here's Why Sarepta is Up More Than 60% So Far This Year

                                    by Zacks Equity Research

                                    Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.

                                      BioMarin's Palynziq Gets FDA Approval for Phenylketonuria

                                      by Zacks Equity Research

                                      BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.

                                        INSYS Gets Negative FDA Recommendation for Pain Candidate

                                        by Zacks Equity Research

                                        INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.

                                          Aeglea Initiates Lung Cancer Combination Study With Keytruda

                                          by Zacks Equity Research

                                          Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.

                                            Endo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down

                                            by Zacks Equity Research

                                            Endo International plc (ENDP) received a huge setback when the FDA directed the company to voluntarily remove its opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market over abuse concerns.

                                              Mallinckrodt (MNK) Commences Phase III Study of StrataGraft

                                              by Zacks Equity Research

                                              Mallinckrodt plc (MNK) has enrolled the first patient in phase III study, assessing StrataGraft regenerative skin tissue for promoting autologous skin regeneration in patients with thermal burns.

                                                Kite Pharma (KITE) Releases Data on Lead Drug for Leukemia

                                                by Zacks Equity Research

                                                Kite Pharma, Inc. (KITE) announced results from phase I trial, ZUMA-3, on lead candidateKTE-C19 (axicabtagene ciloleucel) in adults with high burden relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

                                                  Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA

                                                  by Zacks Equity Research

                                                  Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP).